Advances towards the use of gastrointestinal tumor patient-derived organoids as a therapeutic decision-making tool

In December 2022 the US Food and Drug Administration (FDA) removed the requirement that drugs in development must undergo animal testing before clinical evaluation, a declaration that now demands the establishment and verification of ex vivo preclinical models that closely represent tumor complexity...

Descripción completa

Detalles Bibliográficos
Autores principales: Obreque, Javiera, Vergara-Gómez, Luis, Venegas, Nicolás, Weber, Helga, Owen, Gareth I., Pérez-Moreno, Pablo, Leal, Pamela, Roa, Juan Carlos, Bizama, Carolina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10693174/
https://www.ncbi.nlm.nih.gov/pubmed/38041132
http://dx.doi.org/10.1186/s40659-023-00476-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10693174/
https://www.ncbi.nlm.nih.gov/pubmed/38041132
http://dx.doi.org/10.1186/s40659-023-00476-9

Ejemplares similares